EPGNF - Epigenomics AG

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in EUR. All numbers in thousands
Breakdown
ttm
2021-12-31
2020-12-31
2019-12-31
Total Revenue
567
6,203
842
1,125
Cost of Revenue
138
136
145
253
Gross Profit
429
6,067
697
872
Operating Expenses
Research Development
5,855
3,111
3,659
7,340
Selling General and Administrative
3,943
4,437
3,467
4,523
Total Operating Expenses
9,257
10,229
10,811
15,974
Operating Income or Loss
-8,828
-4,162
-10,114
-15,102
Interest Expense
85
52
55
63
Income Before Tax
-7,248
-2,410
-11,663
-14,566
Income Tax Expense
7
18
23
2,454
Income from Continuing Operations
-7,255
-2,428
-11,686
-17,020
Net Income
-7,255
-2,428
-11,686
-17,020
Net Income available to common shareholders
-7,255
-2,428
-11,686
-17,020
Basic EPS
-
-0.88
-8.08
-14.32
Diluted EPS
-
-0.88
-8.08
-14.32
Basic Average Shares
-
2,802
1,445
1,188
Diluted Average Shares
-
2,802
1,445
1,188
EBITDA
-
-1,939
-11,073
-13,990